Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
MLA Diagnostics logo — Developing a revolutionary prognostic test for early stage m...

MLA Diagnostics

Developing a revolutionary prognostic test for early stage melanoma

Founded 2019 The Netherlands The Netherlands 9 employees Series Unknown Health Care, Medical Devices

General Information

Company Name MLA Diagnostics
Founded Year 2019
Location The Netherlands The Netherlands +1
Employees 9
Industries Health Care, Medical Devices
Funding Stage Series Unknown
Social

Get notified when MLA Diagnostics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About MLA Diagnostics

MLA Diagnostics is a health care startup based in The Netherlands, founded in 2019. The company is focused on developing a revolutionary prognostic test for early stage melanoma, the most deadly form of skin cancer. Their innovative product is an in vitro diagnostic (IVD) method that aims to provide more accurate prognostic information for melanoma patients, helping to determine the risk of metastasis and enabling personalized treatment plans. The Venture Round investment on 29 November 2023 involved Brightlands Life Sciences Ventures, NV Industriebank LIOF, and NLC as investors. MLA Diagnostics' solution addresses the limitations of current prognostic tools, potentially offering significant advancements in melanoma treatment and patient outcomes.

Taxonomy: Melanoma, Skin cancer, Prognostic test, IVD method, Pathologist, Metastatic risk, Early diagnosis, Cancer treatment, Innovation, Medical technology

Funding Rounds & Investors (2)

View All
Funding Stage Amount Investors Lead Investors Date
Venture Round •••••• 3
Investor Investor
•••• •••• 		29 Nov 2023
Pre Seed Round •••••• 1 •••• •••• 05 Apr 2019

MLA Diagnostics Alternatives & Competitors

MLA Diagnostics vs
AMLo Biosciences
AMLo Biosciences United Kingdom

Developing an innovative prognostic test for early-stage cutaneous melanoma

Series Unknown
22 employees
Biotechnology
MLA Diagnostics vs
Castle Biosciences, Inc.
Castle Biosciences, Inc. United States

Improving health through innovative tests that guide patient care

Post Ipo Equity
744 employees
Biotechnology, Health Care
MLA Diagnostics vs
Probmet Therapeutics
Probmet Therapeutics Denmark

An oncology therapeutics company developing new targeted treatments for breast cancer brain metastat...

Convertible Note
2 employees
Health Care, Health and Wellness

FAQ About MLA Diagnostics

Developing a revolutionary prognostic test for early stage melanoma
MLA Diagnostics was founded in 2019.
MLA Diagnostics is headquartered in The Netherlands.
MLA Diagnostics operates in the following industries: Health Care, Medical Devices.
MLA Diagnostics has approximately 9 employees.
MLA Diagnostics has completed 2 funding rounds. The latest funding stage is Series Unknown.
Top alternatives and competitors to MLA Diagnostics include AMLo Biosciences, Castle Biosciences, Inc., Probmet Therapeutics, MetaGuideX Ltd, Melanoma Research Foundation. These companies operate in related industries and serve comparable markets. You can compare them side by side on Bounce Watch.
MLA Diagnostics and AMLo Biosciences are both companies in similar industries. Compare their funding, team size, growth signals, and market position on Bounce Watch to see which one fits your needs.

Don't just browse. Track.

Signal Tracker monitors MLA Diagnostics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy